MedInvest Biotech & Pharma Investor Conference
Palo Alto, CA 94304
Event summary
This two-day conference will feature in-person and virtual presentations from companies developing and/or commercializing technologies across a spectrum of indications, including oncology, immunology, neurology, cardiology, diabetes, infectious diseases, pulmonary diseases, autoimmune diseases, respiratory diseases, urology, endocrinology, dermatology and pain management.
Attendees of this conference are active investors in pharma, biotech and other life sciences companies. The event will also feature talks by key industry opinion leaders, investor panel discussions and insightful conversations on partnering, facilitating collaborations, licensing, and technology analysis and marketing.
Join the leading life sciences and healthcare venture capitalists, family office representatives, lawyers, pharma executives, and private and public biotech and pharmaceuticals companies and foundations for a discussion on trends, opportunities and risks in life sciences investing.
For more information, please email Cooley’s life sciences marketing.
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our legal notices.